Hamel Patel

This study links ASD common genetic variants to regional brain volume differences in newborns, finding positive associations with frontal and fronto-temporal volumes and negative associations with parietal and parieto-occipital volumes.

This paper conducts a genome-wide association study in Nigerian sickle cell disease patients to identify genetic variants associated with fetal hemoglobin levels, finding significant associations at BCL11A and HBS1L-MYB and novel signals in the Nigerian cohort.

The paper investigates the role of common genetic variation in neonatal subcortical brain development by examining SNP associations and polygenic scores from adult studies.

COPILOT automates GWAS quality control for Illumina genotyping data, improving sample call rates and identifying data issues across two cohorts.

The paper develops two gene expression classification models for Alzheimer’s Disease using blood-derived data, finding that including mixed controls improves specificity but reduces sensitivity.

This study compares transcriptomic profiles of asymptomatic and symptomatic Alzheimer's brains to identify early molecular changes associated with disease vulnerability.

This paper performs a meta-analysis of Alzheimer's disease brain transcriptomic data to identify differentially expressed genes and pathways specific to AD, finding 323-1023 genes per brain region and enriched pathways in protein metabolism and viral components.

This paper conducts a meta-analysis showing that CYP2C19 poor metabolizers have better antidepressant efficacy but similar side effects compared to extensive metabolizers.

This study identifies two SNPs associated with antidepressant response in GENDEP and STAR*D studies but finds limited replication in independent cohorts.

This study uses Bayesian logistic regression to assess if genetic risk factors predict amyloid burden in non-demented individuals, finding that known factors like age and APOE are more predictive than polygenic risk scores.

This study investigates whether polygenic risk scores (PRS) can predict antidepressant response in MDD, finding no significant predictive effect.